Anoixis Corporation is a pharmacometric service provider with a mission to revolutionize drug development by fostering innovation and transforming the process into a scientific endeavor. Founded in 2006 and based in United States, the company takes pride in its leadership position in skilled pharmacometric service for breakthrough drug development. With a team of experts drawn from various fields including drug development, pharmacometrics, clinical pharmacology, pharmaceutical science, pharmacy, drug evaluation, regulation, mathematical modeling, and simulation, Anoixis offers a wide range of services such as design and analysis of efficacy and safety studies, population pharmacokinetic modeling, population pharmacokinetic/pharmacodynamic modeling, dose selection, and clinical trial simulation. The company's commitment to integrity and extensive experience in the industry is reflected in its publications in peer-reviewed journals and presentations at scientific meetings. Anoixis Corporation presents an opportunity for venture capital with its innovative approach to drug development and extensive expertise in pharmacometrics.
There is no investment information
No recent news or press coverage available for Anoixis Corporation.
We care about your data, and we'd love to use cookies make your experience better.